Abstract
Primary Sjögren’s syndrome (pSS) is a chronic systemic inflammatory autoimmune disease characterized by lymphocytic infiltrates in exocrine glands. Current approaches do not control harmful autoimmune attacks or prevent irreversible damage and have considerable side effects. Mesenchymal stem cells (MSCs) have been effective in the treatment of several autoimmune diseases. The objective of this review is to illustrate the potential therapeutic role of MSCs in pSS. We summarize the recent advances in what is known about their immunomodulatory function and therapeutic applications in pSS. MSC transfusion can suppress autoimmunity and restore salivary gland secretory function in mouse models and patients with pSS by inducing regulatory T cells, suppressing Th1, Th17, and T follicular helper cell responses. In addition, MSCs can differentiate into salivary epithelial cells, presenting an option as a suitable alternative treatment. We also discuss current bioengineering methods which improve functions of MSCs for pSS. However, there remain many challenges to overcome before their wide clinical application.
| Original language | English (US) |
|---|---|
| Article number | 4357865 |
| Journal | Stem Cells International |
| Volume | 2018 |
| DOIs | |
| State | Published - Jan 1 2018 |
Fingerprint
All Science Journal Classification (ASJC) codes
- Molecular Biology
- Cell Biology
Cite this
}
Mesenchymal stem cells in primary Sjögren’s syndrome : Prospective and challenges. / Chen, Weiqian; Yu, Ye; Ma, Jilin; Olsen, Nancy; Lin, Jin.
In: Stem Cells International, Vol. 2018, 4357865, 01.01.2018.Research output: Contribution to journal › Review article
TY - JOUR
T1 - Mesenchymal stem cells in primary Sjögren’s syndrome
T2 - Prospective and challenges
AU - Chen, Weiqian
AU - Yu, Ye
AU - Ma, Jilin
AU - Olsen, Nancy
AU - Lin, Jin
PY - 2018/1/1
Y1 - 2018/1/1
N2 - Primary Sjögren’s syndrome (pSS) is a chronic systemic inflammatory autoimmune disease characterized by lymphocytic infiltrates in exocrine glands. Current approaches do not control harmful autoimmune attacks or prevent irreversible damage and have considerable side effects. Mesenchymal stem cells (MSCs) have been effective in the treatment of several autoimmune diseases. The objective of this review is to illustrate the potential therapeutic role of MSCs in pSS. We summarize the recent advances in what is known about their immunomodulatory function and therapeutic applications in pSS. MSC transfusion can suppress autoimmunity and restore salivary gland secretory function in mouse models and patients with pSS by inducing regulatory T cells, suppressing Th1, Th17, and T follicular helper cell responses. In addition, MSCs can differentiate into salivary epithelial cells, presenting an option as a suitable alternative treatment. We also discuss current bioengineering methods which improve functions of MSCs for pSS. However, there remain many challenges to overcome before their wide clinical application.
AB - Primary Sjögren’s syndrome (pSS) is a chronic systemic inflammatory autoimmune disease characterized by lymphocytic infiltrates in exocrine glands. Current approaches do not control harmful autoimmune attacks or prevent irreversible damage and have considerable side effects. Mesenchymal stem cells (MSCs) have been effective in the treatment of several autoimmune diseases. The objective of this review is to illustrate the potential therapeutic role of MSCs in pSS. We summarize the recent advances in what is known about their immunomodulatory function and therapeutic applications in pSS. MSC transfusion can suppress autoimmunity and restore salivary gland secretory function in mouse models and patients with pSS by inducing regulatory T cells, suppressing Th1, Th17, and T follicular helper cell responses. In addition, MSCs can differentiate into salivary epithelial cells, presenting an option as a suitable alternative treatment. We also discuss current bioengineering methods which improve functions of MSCs for pSS. However, there remain many challenges to overcome before their wide clinical application.
UR - http://www.scopus.com/inward/record.url?scp=85062892147&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85062892147&partnerID=8YFLogxK
U2 - 10.1155/2018/4357865
DO - 10.1155/2018/4357865
M3 - Review article
C2 - 30305818
AN - SCOPUS:85062892147
VL - 2018
JO - Stem Cells International
JF - Stem Cells International
SN - 1687-9678
M1 - 4357865
ER -